Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, an open-label, dose-escalation safety and efficacy study of Trans Sodium Crocetinate (TSC) in newly diagnosed glioblastoma multiforme patients

Next Previous
Trial Profile

A phase 2, an open-label, dose-escalation safety and efficacy study of Trans Sodium Crocetinate (TSC) in newly diagnosed glioblastoma multiforme patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CervoMed; Diffusion Pharmaceuticals

Most Recent Events

  • 15 Aug 2023 According to a Diffusion Pharmaceuticals media release, in connection with the proposed merger with EIP, and pending its conclusion, Diffusion previously paused the initiation of this study.
  • 14 Nov 2022 According to a Diffusion Pharmaceuticals media release, initial data readouts from the dose-escalation phase of this study expected to be available within one year of the first patient being dosed.
  • 11 Aug 2022 According to a Diffusion Pharmaceuticals media release, initial imaging readouts from the trial are expected to be available within one year of study initiation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top